- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
An Indian real-world experience of intravenous fosnetupitant-palonosetron (IV NEPA) in preventing delayed and extended delayed CINV. (Hall A; Poster Bd #: 199) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2820; Cisplatin-Paclitaxel (19.10%) and Carboplatin-Paclitaxel (35.39%) were the most common HEC and MEC regimens respectively... IV NEPA demonstrated high efficacy and good tolerability in a real world Indian setting, exhibiting response rates of >92% in both delayed and extended delayed phases in patients receiving HEC/MEC regimens.
- |||||||||| Akynzeo IV (fosnetupitant/palonosetron) / Helsinn, Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Journal, CINV: Antiemetic use and chemotherapy induced nausea and vomiting (Pubmed Central) - Mar 29, 2023 These results complement clinical trial data and published economic models supporting the use of NEPA as a safe, effective, and cost-saving antiemetic for patients undergoing chemotherapy. Materials & PrecisionQ analyzed its database to evaluate CINV
- |||||||||| Arokaris (fosnetupitant) / Helsinn, Otsuka, netupitant (Ro 67-3189) / Helsinn, Otsuka
Review, Journal, CINV: Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective. (Pubmed Central) - Mar 9, 2023 Fosnetupitant is one of the standard treatments for the prevention of CINV in patients who are receiving highly (any treatment where CINV occurs in more than 90% of patients) or moderately (where CINV occurs in 30-90% of patients) emetogenic chemotherapies. The aim of this commentary is to describe the mechanism of action, tolerability, and antiemetic efficacy of single-agent fosnetupitant in the prevention of CINV, and to discuss its clinical application, in order to aid optimal use.
- |||||||||| fosnetupitant (Pro-NETU) / Helsinn, Otsuka, Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, netupitant (Ro 67-3189) / Helsinn, Otsuka
Clinical, P3 data, Journal, CINV: Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE). (Pubmed Central) - Mar 6, 2022 The choice of antiemetics to prevent CINV among cancer patients receiving HEC may impact real-world outcomes and healthcare resource use. In this exploratory analysis, fosnetupitant appeared to be more effective than fosaprepitant in preventing CINV associated with cisplatin-based HEC during the extended 7-day period following chemotherapy.
- |||||||||| Varubi (rolapitant oral) / TerSera Therap, GSK
Retrospective data, Review, Journal: Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (Pubmed Central) - Dec 16, 2021 For people receiving HEC, synthesised evidence does not suggest one superior treatment for prevention and control of chemotherapy-induced nausea and vomiting. For people receiving MEC, synthesised evidence does not suggest superiority for treatments including both NK₁ and 5-HT₃ inhibitors when compared to treatments including 5-HT₃ inhibitors only. Rather, the results of our NMA suggest that the choice of 5-HT₃ inhibitor may have an impact on treatment efficacy in preventing CINV. When interpreting the results of this systematic review, it is important for the reader to understand that NMAs are no substitute for direct head-to-head comparisons, and that results of our NMA do not necessarily rule out differences that could be clinically relevant for some individuals.
- |||||||||| dexamethasone / Generic mfg.
Clinical, Journal: Recent Advances in Antiemetics: New Formulations of 5-HT3 Receptor Antagonists in Adults. (Pubmed Central) - Apr 24, 2021 Importantly, there were no injection-site or hypersensitivity reactions associated with IV NEPA. Nurses play a critical role in understanding and using new antiemetic formulations and updated antiemetic guidelines in their practices.This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- |||||||||| Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Preclinical, Journal: Modification of i-GONAD Suitable for Production of Genome-Edited C57BL/6 Inbred Mouse Strain. (Pubmed Central) - Mar 16, 2021 Unfortunately, the most widely used electroporators employ a constant voltage, and thus we explored conditions allowing the generation of a 100 mA current using two electroporators: NEPA21 (Nepa Gene Co., Ltd.) and GEB15 (BEX Co., Ltd.)...i-GONAD performed on PMSG-treated pregnant B6 females under conditions of average resistance of 367 Ω and average voltage of 116 mA resulted in the production of pregnant females at a rate of 56% (5/9 mice), from which 23 fetuses were successfully delivered. Nine (39%) of these fetuses exhibited successful genome editing at the target locus.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn, netupitant (Ro 67-3189) / Helsinn, Otsuka
Clinical, P3 data, Review, Journal, CINV: Efficacy of intravenous NEPA, a fixed NK/5-HT receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. (Pubmed Central) - Jan 23, 2021 This paper presents an overview of the efficacy of intravenous (IV) NEPA (fixed combination of the NKRA, fosnetupitant, and 5-HTRA, palonosetron) relative to oral NEPA and also to historical data for other NKRA regimens...The overall (0-120 h) complete response (no emesis, no rescue use), no emesis, and no significant nausea rates for IV NEPA were similar to that of oral NEPA and were consistently numerically higher than historical NKRA regimens. As a single-dose prophylactic antiemetic combination given with dexamethasone, IV NEPA is a highly effective and convenient guideline-compliant antiemetic agent which may offer a safety benefit over other IV NKRA regimens due to its lack of associated hypersensitivity and injection-site reactions.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Decadron (dexamethasone) / Merck (MSD), Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Clinical, PK/PD data, Journal, CINV: Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. (Pubmed Central) - Feb 28, 2020 NEPA provides additional administration convenience. Clinical trial registration number: EudraCT 2015-004750-18.
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, cyclophosphamide oral / Generic mfg., Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Clinical, P3 data, Journal, CINV: Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. (Pubmed Central) - Dec 8, 2019 Hypersensitivity reactions and anaphylaxis have been reported with other IV NKRAs, most commonly with fosaprepitant in the AC setting. Importantly, there were no injection-site or hypersensitivity reactions associated with IV NEPA.
|